A Phase 3 interventional study of Methylphenidate (MPH) and Placebo in Brain Tumor, Pediatric, Cancer-related Fatigue and Methylphenidate, sponsored by Odense University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 6 Years to 27 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Odense University Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Brain Neoplasms with a site in Denmark — 10 open to participants now, 14 under way, 3 of them phase 3. Brain Neoplasms · Denmark.
Among the 38 studies in Brain Neoplasms with a site in Denmark, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 10 of the 13 other live ones, and was the 34th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →10 of the 38 studies in Brain Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Aalborg University Hospital · Sites in Denmark
Ages 18+
Institut de Recherches Internationales Servier · Sites in Denmark, United States, Australia and 7 more countries
Ages 18+
Anders Rosendal Korshøj · Sites in Denmark
Ages 18+
UMC Utrecht · Sites in Denmark, United States, Australia and 6 more countries
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18–100 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 6 Years to 27 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 7 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 80 across the 27 interventional studies, 150 across the 11 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 38 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Brain Neoplasms with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT07558395Institut National de la Santé Et de la Recherche Médicale, FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | 2026-12 |
| NCT06413706Eli Lilly and CompanyA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | 2027-02 |
| NCT07590726Rigshospitalet, DenmarkPIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Brain Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).
If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any known to methylphenidate as outlined below:
A) to the active substance or any listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.
Drug: Methylphenidate (MPH) · Drug: Placebo
Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.
Drug: Methylphenidate (MPH) · Drug: Placebo
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.
10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate).
PedsQL Multidimensional Fatigue Scale (MFS)
Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).
Time frame: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
PedsQL Multidimensional Fatigue Scale (MFS)
Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.
Time frame: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
Behaviour Rating Inventory of Executive Function (BRIEF)
Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.
Time frame: At baseline, at Week 6, and Week 16.
Connor's Continuous Performance Test (CPT) Online Suite
Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.
Time frame: At baseline, at Week 6, and Week 16.
Wechsler Coding
Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.
Time frame: At baseline, at Week 6, and Week 16.
Wechsler Digit Span
Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.
Time frame: At baseline, at Week 6, and Week 16.
PedsQL Generic Core Scales
Changes from baseline in self and parent-reported measures of Health Related Quality of Life.
Time frame: At baseline, at Week 6, and Week 16.
Accelerometry (Axivity AX3)
Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.
Time frame: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
Barkley's Stimulant Side Effect Rating Scale (SSERS)
Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.
Time frame: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2029, 51 months after the start.
Of 56 phase 3 interventional studies under Brain Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 269. This study's planned 51 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylphenidate